These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2574687)

  • 1. Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine reduces the release of [3H]dopamine from rat striatal slices.
    Kurstjens NP; Cantrill RC
    Eur J Pharmacol; 1989 Oct; 169(1):147-52. PubMed ID: 2574687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical investigations in vitro with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in preparations of rat brain.
    Markstein R; Lahaye D
    Eur J Pharmacol; 1984 Nov; 106(2):301-11. PubMed ID: 6335691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones.
    Boyce S; Kelly E; Reavill C; Jenner P; Marsden CD
    Biochem Pharmacol; 1984 Jun; 33(11):1747-52. PubMed ID: 6610420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway.
    Bradbury AJ; Costall B; Domeney AM; Jenner P; Kelly ME; Marsden CD; Naylor RJ
    Nature; 1986 Jan 2-8; 319(6048):56-7. PubMed ID: 3484542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
    Sirinathsinghji DJ; Heavens RP; McBride CS
    Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine.
    Schmidt CJ; Matsuda LA; Gibb JW
    Eur J Pharmacol; 1984 Aug; 103(3-4):255-60. PubMed ID: 6333347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioural effects and supersensitivity in the rat following intranigral MPTP and MPP+ administration.
    Lange KW
    Eur J Pharmacol; 1990 Jan; 175(1):57-61. PubMed ID: 2323346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+.
    Shen RS; Abell CW; Gessner W; Brossi A
    FEBS Lett; 1985 Sep; 189(2):225-30. PubMed ID: 3876242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
    Javitch JA; D'Amato RJ; Strittmatter SM; Snyder SH
    Proc Natl Acad Sci U S A; 1985 Apr; 82(7):2173-7. PubMed ID: 3872460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine receptor system.
    Lau YS; Fung YK
    Brain Res; 1986 Mar; 369(1-2):311-5. PubMed ID: 3486026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter.
    Clarke PB; Reuben M
    Br J Pharmacol; 1995 Jan; 114(2):315-22. PubMed ID: 7881731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of prolyl-leucyl-glycine (MIF-1) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine levels of the striatum].
    Sheng JG
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Aug; 22(4):213-5, 253. PubMed ID: 2575971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of striatal dopamine by the N-oxide of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Lau YS; Fung YK; Trobough KL; Cashman JR; Wilson JA
    Neurotoxicology; 1991; 12(2):189-99. PubMed ID: 1956580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of dopamine uptake and cocaine binding in mouse striatum by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sershen H; Reith ME; Hashim A; Lajtha A
    Eur J Pharmacol; 1984 Jun; 102(1):175-8. PubMed ID: 6332738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation by the tetraphenylboron anion of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its pyridinium metabolite.
    Heikkila RE; Hwang J; Ofori S; Geller HM; Nicklas WJ
    J Neurochem; 1990 Mar; 54(3):743-50. PubMed ID: 2303810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on striatal dopamine receptors in C57BL/6 mice.
    Bhargava HN; Perlow MJ
    Toxicol Lett; 1988 Mar; 40(3):219-24. PubMed ID: 3258448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on presynaptic dopamine uptake sites in the mouse striatum.
    Donnan GA; Kaczmarczyk SJ; Rowe PJ; Figdor R; Mendelsohn FA
    J Neurol Sci; 1986 Jun; 74(1):111-9. PubMed ID: 3487620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
    Jarvis MF; Wagner GC
    Life Sci; 1985 Jan; 36(3):249-54. PubMed ID: 3871245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of prenatal treatment with MPTP or MPP+ on the development of dopamine-mediated behaviors in rats.
    Weissman EM; Norman AB; Calderon SF; Zubrycki EM; el-Etri MM; Shipley MT; Sanberg PR
    Pharmacol Biochem Behav; 1989 Nov; 34(3):545-51. PubMed ID: 2623012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.